1. |
Paul Wright G, Davis AT, Koehler TJ, et al. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas. Ann Surg Oncol, 2014, 21(11): 3497-3503.
|
2. |
Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med, 1973, 73(9): 1078-1082.
|
3. |
Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization, 2000.
|
4. |
Aydiner A, Sen F, Tambas M, et al. Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment. Medicine (Baltimore), 2015, 94(52): e2341.
|
5. |
丁华野, 皋岚湘. 化生性乳腺癌的诊断和鉴别诊断. 浙江肿瘤, 1996, 2(4): 199-202.
|
6. |
The World Health Organization. Histological typing of breast tumors. Neoplasma, 1983, 30(1): 113-123.
|
7. |
Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. 4th ed. Geneva: World Health Organization, 2012.
|
8. |
Abd El hafez A, Abd El-aty S. Analysis of metaplastic breast carcinoma: FNAC; histopathology and immunohistochemistry are complementary for diagnosis. Breast Dis, 2013, 34(2): 67-75.
|
9. |
Abouharb S, Moulder S. Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy. Curr Oncol Rep, 2015, 17(3): 431.
|
10. |
Dieci MV, Orvieto E, Dominici M, et al. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist, 2014, 19(8): 805-813.
|
11. |
Myint ZW, Raparla S, Kamugisha LK. Metaplastic breast cancer with chondroid differentiation. J Community Hosp Intern Med Perspect, 2015, 5(4): 28935.
|
12. |
Schwartz TL, Mogal H, Papageorgiou C, et al. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol, 2013, 2(1): 31.
|
13. |
Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol, 2012, 25(2): 178-184.
|
14. |
Leibl S, Gogg-Kammerer M, Sommersacher A, et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol, 2005, 29(3): 347-353.
|
15. |
Cooper CL, Karim RZ, Selinger C, et al. Molecular alterations in metaplastic breast carcinoma. J Clin Pathol, 2013, 66(6): 522-528.
|
16. |
Lorenzatti G, Huang W, Pal A, et al. CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer. J Cell Sci, 2011, 124(Pt 10): 1752-1758.
|
17. |
高月, 鲁亚晶, 苗杨, 等. Snail 和 E-cad 在化生性乳腺癌中的表达及其临床意义. 临床肿瘤学杂志, 2015, 20(9): 799-803.
|
18. |
Liu YN, Lee WW, Wang CY, et al. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene, 2005, 24(56): 8277-8290.
|
19. |
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol, 2015, 26(8): 1533-1546.
|
20. |
Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology, 2006, 49(1): 10-21.
|
21. |
Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology, 2008, 52(1): 108-118.
|
22. |
Lim KH, Oh DY, Chie EK, et al. Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity. Jpn J Clin Oncol, 2010, 40(2): 112-118.
|
23. |
Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res, 2009, 15(7): 2302-2310.
|
24. |
Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol, 2005, 58(7): 700-704.
|
25. |
Min Kim H, Kim SK, Jung WH, et al. Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer. Tumour Biol, 2015, 36(2): 1207-1212.
|
26. |
Leo F, Bartels S, Mägel L, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch, 2016, 469(2): 191-201.
|
27. |
Wang H, Guan B, Shi Q, et al. May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis. Med Oncol, 2011, 28(1): 42-50.
|
28. |
Kuroda N, Fujishima N, Inoue K, et al. Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas. Med Mol Morphol, 2008, 41(2): 117-120.
|
29. |
Sanguinetti A, Lucchini R, Santoprete S, et al. Metaplastic carcinoma of the breast: Treatment, results and prognostic factors based on international literature. Ann Ital Chir, 2014, 85(2): 109-113.
|
30. |
Salimoğlu S, Sert İ, Emiroğlu M, et al. Metaplastic breast carcinoma: analysis of clinical and pathologic characteristics—a case series. J Breast Health, 2016, 12(2): 63-66.
|
31. |
Terando AM, Agnese DM, Holmes DR. Treatment and prognosis of rare breast cancers. Ann Surg Oncol, 2015, 22(10): 3225-3229.
|
32. |
Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat, 2007, 101(3): 349-353.
|
33. |
Günhan-Bilgen I, Memiş A, Ustün EE, et al. Metaplastic carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol, 2002, 178(6): 1421-1425.
|
34. |
Arpino G, Clark GM, Mohsin S, et al. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer, 2002, 94(8): 2119-2127.
|
35. |
Velasco M, Santamaría G, Ganau S, et al. MRI of metaplastic carcinoma of the breast. AJR Am J Roentgenol, 2005, 184(4): 1274-1278.
|
36. |
Leyrer CM, Berriochoa CA, Agrawal S, et al. Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res Treat, 2017, 165(3): 499-504.
|
37. |
Zhang Y, Lv F, Yang Y, et al. Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major chinese cancer center. PLoS One, 2015, 10(6): e0131409.
|
38. |
Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia, 2010, 15(2): 253-260.
|
39. |
Xiao M, Yang Z, Tang X, et al. Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast. Oncol Lett, 2017, 14(2): 1971-1978.
|
40. |
Tanabe Y, Tsuda H, Yoshida M, et al. Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. Cancer Sci, 2017, 108(7): 1520-1529.
|
41. |
Swathy PU, Arunalatha P, Chandramouleeswari K, et al. Adenosquamous variant of metaplastic carcinoma of breast—an unusual histological variant. J Clin Diagn Res, 2015, 9(2): E5-E6.
|
42. |
Khan HN, Wyld L, Dunne B, et al. Spindle cell carcinoma of the breast: a case series of a rare histological subtype. Eur J Surg Oncol, 2003, 29(7): 600-603.
|
43. |
Zhou N, Liu C, Hou H, et al. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma. Oncotarget, 2016, 7(44): 72373-72379.
|
44. |
Huang W, Pal A, Kleer CG. On how CCN6 suppresses breast cancer growth and invasion. J Cell Commun Signal, 2012, 6(1): 5-10.
|
45. |
Martin EE, Huang W, Anwar T, et al. MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas. Oncogene, 2017, 36(16): 2275-2285.
|
46. |
Dave B, Granados-Principal S, Zhu R, et al. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci U S A, 2014, 111(24): 8838-8843.
|
47. |
Dave B, Gonzalez DD, Liu ZB, et al. Role of RPL39 in metaplastic breast cancer. J Natl Cancer Inst, 2016, 109(6). pii: djw292.
|
48. |
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev, 2010, 236: 219-242.
|
49. |
Joneja U, Vranic S, Swensen J, et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol, 2017, 70(3): 255-259.
|
50. |
Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One, 2014, 9(2): e88557.
|
51. |
Adams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer, 2017, 3: 8.
|
52. |
Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene, 2008, 27(55): 6958-6969.
|
53. |
Tampakis A, Tampaki EC, Trafalis D, et al. Nestin and CD146 expression in metaplastic breast cancer: stem-cell therapy in need? Lessons reported from a male patient. Eur Rev Med Pharmacol Sci, 2017, 21(18): 4137-4140.
|
54. |
Asaduzzaman M, Constantinou S, Min H, et al. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Res Treat, 2017, 163(3): 461-474.
|
55. |
Edenfield J, Schammel C, Collins J, et al. Metaplastic breast cancer: molecular typing and identification of potential targeted therapies at a single institution. Clin Breast Cancer, 2017, 17(1): e1-e10.
|
56. |
Zhang X, Zhang B, Zang F, et al. Clinical features and treatment of squamous cell carcinoma of the breast. Onco Targets Ther, 2016, 9: 3181-3185.
|
57. |
Rakha EA, Tan PH, Varga Z, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer, 2015, 112(2): 283-289.
|
58. |
El Zein D, Hughes M, Kumar S, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer, 2017, 17(5): 382-391.
|
59. |
Lee H, Jung SY, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol, 2012, 65(5): 441-446.
|
60. |
Song Y, Liu X, Zhang G, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol, 2013, 11: 129.
|